Navigation Links
Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
Date:12/5/2011

GREENWOOD VILLAGE, Colo., Dec. 5, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE—News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced it has signed an agreement to acquire certain rights relating to a patented orally disintegrating tablet (ODT) drug delivery technology that can be used worldwide to elevate the market acceptance of Ampio's Zertane™ product for premature ejaculation. The Zertane™ ODT formulation allows for rapid oral absorption, ease of use without the need for liquids and avoids unpleasant bitter taste. This acquisition provides additional intellectual property to protect Zertane™ ODT's unique formulation, over and above the many method of use claims for Zertane™ contained in patents Ampio already owns.  The Company indicated that acquisition of the rights to this technology is expected to speed and facilitate Ampio's filing of marketing authorization applications for product regulatory approvals of Zertane™ worldwide and is important for the additional planned licensing and pricing agreements currently in negotiations.  The completion of the transaction is subject to customary conditions, including a certain third party consent and successful completion of a technology and materials transfer plan more fully described in a Form 8-K to be filed shortly.

"This acquisition of this technology is an important step in the manufacturing and commercialization plan for Zertane™. This agreement demonstrates our commitment to the fast and successful launch of a unique dosage and formulation of Zertane™. The Zertane™ commercialization plan is on course as outlined in the previous press releases and securities filings. We are committed to complete the development of a combination product of Zertane™ with a PDE5 inhibitor to simultaneously treat both premature ejaculation and erectile dysfunction. Our strategy with this line of products is to expeditiously pursue multiple licensing partners worldwide." stated Don Wingerter, Ampio's CEO.

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease and male sexual dysfunction.  The product pipeline includes new uses of previously approved drugs and new molecular entities ("NMEs").  By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective, while their shorter development times can significantly increase near-term value.  A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.  For more information about Ampio, please visit our website, www.ampiopharma.com.  

Forward-Looking Statements

Ampio's statements made in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions.  These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events.  The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact:

Investor Relations, Ampio Pharmaceuticals, Inc.  720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 ... that validate the use of MMprofiler with SKY92, the ... myeloma (MM). In a poster presentation at the 22 ... in Madrid, Spain , SkylineDx researchers ... high-risk elderly patients. In a separate ...
(Date:6/20/2017)... Inc. (NYSE: HRC), will host its fiscal third quarter 2017 ... beginning at 7:30 a.m. (CDT) / 8:30 a.m. (EDT). ... the conference call, dial (877) 304-8969 (domestic) or (631) 291-4543 ... prior to the start to allow time to connect. The ... Webcast: A simultaneous webcast of the call will be ...
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... ... 23, 2017 , ... Yesterday, U.S. Senate Republicans revealed details ... and replace the Affordable Care Act (ACA). Like the bill narrowly passed by ... a public health insurance program for low-income children, pregnant women, parents of dependent ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and antioxidants ... visual loss in these patients. , But how often do ophthalmologists and optometrists in ... patients at risk of or with early symptoms of AMD? A study published ...
Breaking Medicine News(10 mins):